Tag: transmucosal drug delivery devices market size

  • Transmucosal Drug Delivery Devices Market Growth Outlook Reveals A CAGR Of 8.1% And A Market Value Of $81.52 Billion By 2030

    Transmucosal Drug Delivery Devices Market Growth Outlook Reveals A CAGR Of 8.1% And A Market Value Of $81.52 Billion By 2030

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    The market for transmucosal drug delivery devices is gaining traction as new technologies and patient preferences evolve. This sector is seeing considerable growth driven by innovations in drug formulations and delivery methods, alongside increasing demand for non-invasive medication options. Let’s explore the market’s size, key growth drivers, segmentation, leading companies, industry trends, and regional outlook to understand its trajectory through 2030.

    Transmucosal Drug Delivery Devices Market Size and Projected Growth

    The transmucosal drug delivery devices market has experienced significant expansion in recent years. It is forecasted to grow from $54.63 billion in 2025 to $59.61 billion in 2026, representing a compound annual growth rate (CAGR) of 9.1%. This historical growth has been fueled by the rise of non-invasive drug delivery methods, an increasing need for pain management therapies, growing use of hormone replacement treatments, pharmaceutical formulation advancements, and broader acceptance of transmucosal therapeutic options. Looking ahead, the market is expected to reach $81.52 billion by 2030, expanding at a CAGR of 8.1%. Factors contributing to this forecast include the development of personalized medicine, rising investments in innovative drug delivery platforms, growing demand for devices suitable for home use, expansion of biologics and peptides, and more regulatory approvals for novel delivery systems. Key trends shaping this future growth involve the adoption of buccal and sublingual drug delivery forms, increased demand for rapid-onset therapies, advancements in microneedle and active delivery technologies, stronger focus on patient-friendly designs, and greater attention to dose accuracy and bioavailability.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    Important Drivers Supporting Growth in the Transmucosal Drug Delivery Devices Market

    One of the main forces propelling the growth of this market is the increasing prevalence of chronic diseases worldwide. Chronic conditions, which develop slowly and require long-term management, are becoming more common due to factors such as aging populations, lifestyle changes, environmental influences, and urbanization. These diseases often demand consistent and effective medication delivery, which transmucosal devices can provide by ensuring controlled release and improved patient adherence.

    For instance, in June 2024, the National Health Service in the UK reported that 3,615,330 patients registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023. This figure represents an 18% rise from 3,065,825 cases in 2022, illustrating the growing chronic disease burden that drives demand for innovative drug delivery solutions like transmucosal devices.

    Key Market Segments and Revenue Drivers in the Transmucosal Drug Delivery Devices Industry

    This market is segmented by multiple categories to reflect the diversity of devices and applications:

    1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, and Vaginal Drug Delivery Devices.

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films and Wafers, Gels, Medicated Confectionery, and others.

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, and other medical uses.

    4) By End User: Academic and research institutions, pharmaceutical and biotech companies, diagnostic laboratories, and hospitals.

    Further sub-segmentation includes specific device types such as Mucoadhesive Buccal Tablets, Buccal Patches, and Buccal Films under buccal delivery; Sublingual Tablets, Films, and Sprays under sublingual delivery; Metered Dose Nasal Sprays, Nasal Powder Devices, and Nasal Gel Applicators under nasal delivery; Rectal Suppositories and Gels; Vaginal Rings, Tablets, and Gels.

    Access The Complete Transmucosal Drug Delivery Devices Market Report:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    Recent Industry Trends Reshaping the Transmucosal Drug Delivery Devices Market

    Leading players in the transmucosal drug delivery space are increasingly focusing on developing smart platforms that enhance drug absorption and patient convenience. One growing area is proprietary transdermal patch technologies, which deliver medications through the skin with controlled release mechanisms, improving therapeutic outcomes and compliance.

    For example, in January 2024, US biotechnology firm Starton Therapeutics Inc introduced STARSILON, a transdermal patch delivery system designed for prolonged therapeutic delivery of challenging active pharmaceutical ingredients (APIs). This innovation broadens options for transdermal drug delivery, particularly for difficult-to-formulate drugs, enhancing efficacy through sustained release.

    Prominent Companies Competing in the Transmucosal Drug Delivery Devices Sector

    The competition within this market is led by well-known organizations including Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., and Maya Biotech Pvt. Ltd. These companies are at the forefront of developing and commercializing advanced transmucosal drug delivery solutions.

    Regional Overview Highlighting Market Opportunities in Transmucosal Drug Delivery Devices

    In 2025, North America held the largest share of the transmucosal drug delivery devices market. Alongside this, the market report covers various regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. These regions collectively offer significant opportunities as the demand for innovative drug delivery technologies grows globally.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Transmucosal Drug Delivery Devices Market Insights On Growth Drivers, Trends, And Opportunities

    Transmucosal Drug Delivery Devices Market Insights On Growth Drivers, Trends, And Opportunities

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Estimated Market Size Of The Transmucosal Drug Delivery Devices Market In 2026, And How Will Its Value Evolve By 2030?

    The transmucosal drug delivery devices market has shown significant growth in recent years. Its size is expected to expand from $54.63 billion in 2025 to $59.61 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.1%. Historically, this market expansion can be attributed to the rise of non-invasive drug delivery methods, increasing demand for pain management treatments, greater utilization of hormone replacement therapies, advancements in pharmaceutical formulation, and widespread acceptance of transmucosal applications.

    Significant expansion is anticipated for the transmucosal drug delivery devices market size over the coming years. By 2030, this market is projected to reach $81.52 billion, expanding at a compound annual growth rate (CAGR) of 8.1%. Factors driving this growth during the projected period include the growing creation of personalized medicine solutions, increased capital allocation towards sophisticated drug delivery platforms, a surging need for home-based drug administration tools, the broadening scope of biologics and peptide-based medications, and more frequent regulatory endorsements for innovative delivery mechanisms. Key developments expected within this timeframe encompass the wider acceptance of buccal and sublingual administration methods, an escalating requirement for quickly acting drug delivery, the advancement of microneedle and active delivery innovations, an elevated focus on user-friendly drug delivery devices, and a heightened priority on precise dosing and biological availability.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    What Key Factors Are Affecting The Transmucosal Drug Delivery Devices Market Demand?

    The increasing incidence of long-term illnesses is anticipated to boost the expansion of the transmucosal drug delivery devices market in the foreseeable future. A chronic disease describes an enduring medical state that usually advances gradually and endures for an extended period, frequently demanding continuous medical intervention to manage its indicators and avert complications. The rise in chronic diseases stems from factors such as lifestyle choices, an aging global populace, environmental influences, difficulties within healthcare systems, and increasing urbanization. In the context of chronic diseases, transmucosal drug delivery devices are employed to facilitate precise and effective medication administration, thereby maintaining consistent therapeutic concentrations essential for symptom management and enhancing patient compliance. As an illustration, the National Health Service, a governmental body in the UK, reported in June 2024 that 3,615,330 people registered with a general practitioner (GP) had received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023. This represented an 18% rise from the 3,065,825 instances recorded in 2022. Consequently, the increasing occurrence of chronic illnesses is propelling the transmucosal drug delivery devices market.

    What Are The Key Segment Divisions In The Transmucosal Drug Delivery Devices Market Segment Structure?

    The transmucosal drug delivery devices market covered in this report is segmented –

    1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films

    2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays

    3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators

    4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels

    5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels

    What Trends Are Influencing Changes In The Transmucosal Drug Delivery Devices Market?

    Leading companies in transmucosal drug delivery devices are creating innovative smart platforms, such as unique transdermal patch delivery systems, which are designed to enhance drug absorption and improve patient compliance and convenience. These proprietary transdermal patch delivery platforms are specialized technologies owned by companies for administering medications through the skin, ensuring controlled release and improved therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, introduced STARSILON, a novel proprietary transdermal patch delivery platform, intended for extended duration to achieve therapeutic delivery of difficult-to-formulate APIs. This development expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.

    Which Organizations Are Engaged In The Transmucosal Drug Delivery Devices Market?

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd

    Get The Full Transmucosal Drug Delivery Devices Market Report:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    Which Region Leads The Transmucosal Drug Delivery Devices Market In Overall Market Size?

    North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Transmucosal Drug Delivery Devices Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2026, By The Business Research Company

    Oral Transmucosal Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report

    Drug Delivery Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Drug Delivery Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Transmucosal Drug Delivery Devices Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

    Global Transmucosal Drug Delivery Devices Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Value Is Expected For The Transmucosal Drug Delivery Devices Market At The End Of The 2026–2030 Forecast Period?

    The transmucosal drug delivery devices market has seen substantial expansion in recent years. It is anticipated to expand from $54.63 billion in 2025 to $59.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. This historical growth is primarily due to the rise of non-invasive drug delivery methods, increased need for pain management therapies, broader application of hormone replacement treatments, innovations in pharmaceutical formulation, and a wider embrace of transmucosal therapies.

    The transmucosal drug delivery devices market is anticipated to experience substantial growth in the upcoming years. It is expected to expand to **$81.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%**. This projected growth throughout the forecast period stems from the increasing progress in personalized medicine solutions, a rise in investments towards sophisticated drug delivery platforms, a burgeoning need for at-home drug administration devices, the expanding applications of biologics and peptide-based drugs, and an uptick in regulatory approvals for innovative delivery systems. Significant trends during this period involve the rising adoption of buccal and sublingual delivery formats, an increasing demand for rapid onset drug administration, the proliferation of microneedle and active delivery technologies, a heightened emphasis on patient-friendly drug delivery devices, and an enhanced focus on achieving dose accuracy and bioavailability.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    What Primary Drivers Are Shaping The Development Of The Transmucosal Drug Delivery Devices Market?

    The transmucosal drug delivery devices market is anticipated to expand due to the increasing prevalence of chronic diseases. A chronic disease is defined as a long-term condition that typically progresses slowly and persists over time, often requiring continuous medical management to control symptoms and prevent complications. The rise in chronic diseases is influenced by lifestyle factors, aging populations, environmental factors, challenges within healthcare systems, and urbanization. Transmucosal drug delivery devices are utilized in chronic diseases to facilitate controlled and efficient medication delivery, ensuring sustained therapeutic levels for symptom management and improved patient adherence. For instance, according to the National Health Service, a UK-based government department, in June 2024, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, which was an 18% increase from 3,065,825 cases in 2022. Consequently, the growing occurrence of chronic diseases is a significant driver for the transmucosal drug delivery devices market.

    What Segment Types Make Up The Transmucosal Drug Delivery Devices Market?

    The transmucosal drug delivery devices market covered in this report is segmented –

    1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films

    2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays

    3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators

    4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels

    5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels

    Which Market Trends Are Creating New Opportunities In The Transmucosal Drug Delivery Devices Market?

    Major companies involved in transmucosal drug delivery devices are developing innovative smart platforms, such as proprietary transdermal patch delivery systems, that enhance drug absorption while improving patient compliance and convenience. These proprietary transdermal patch delivery platforms are specialized technologies owned by companies for administering medications through the skin, ensuring controlled release and enhanced therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, launched STARSILON, a novel proprietary transdermal patch delivery platform, designed for a longer duration to achieve therapeutic delivery of difficult-to-formulate APIs. This expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.

    Who Are The Key Players Driving Competition In The Transmucosal Drug Delivery Devices Market?

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd

    Read the full transmucosal drug delivery devices market report here:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    How Does The Transmucosal Drug Delivery Devices Market Perform Across Major Global Regions?

    North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Transmucosal Drug Delivery Devices Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2026, By The Business Research Company

    Oral Transmucosal Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report

    Drug Delivery Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Drug Delivery Devices Market Report 2026

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Transmucosal Drug Delivery Devices Market Report 2026–2030: Data-Driven Growth Insights

    Global Transmucosal Drug Delivery Devices Market Report 2026–2030: Data-Driven Growth Insights

    Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

    What growth pattern is forecast for the Transmucosal Drug Delivery Devices Market size between 2026 and 2035?

    The transmucosal drug delivery devices market size has demonstrated significant growth over recent years. It is anticipated to expand from $54.63 billion in 2025 to $59.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. Historically, this market expansion can be linked to the increased adoption of non-invasive drug delivery methods, a surging demand for pain management treatments, the expanded application of hormone replacement therapies, innovations in pharmaceutical formulations, and a broader acceptance of transmucosal therapeutic approaches.

    The transmucosal drug delivery devices market size is anticipated to experience robust expansion over the next few years. It is forecast to grow to $81.52 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.1%. This projected growth during the forecast period stems from the increasing development of personalized medicine solutions, rising investments in advanced drug delivery platforms, a growing demand for at-home drug administration devices, the expansion of biologics and peptide-based drugs, and an increase in regulatory approvals for novel delivery systems. Significant trends expected during this forecast period include the increasing adoption of buccal and sublingual delivery formats, a growing demand for rapid onset drug administration, the expansion of microneedle and active delivery technologies, a rising focus on patient-friendly drug delivery devices, and an enhanced emphasis on dose accuracy and bioavailability.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    Which Drivers Are Impacting Market Performance In The Transmucosal Drug Delivery Devices Market?

    The increasing incidence of chronic illnesses is anticipated to drive the expansion of the transmucosal drug delivery devices market moving ahead. A chronic disease is defined as an enduring ailment that usually advances gradually and remains present for an extended period, frequently necessitating continuous medical care to manage its signs and avert further issues. The rise in chronic conditions can be attributed to elements such as lifestyle choices, an aging global demographic, environmental influences, difficulties within healthcare systems, and increasing urbanization. For chronic diseases, transmucosal drug delivery devices serve to administer medications in a controlled and effective manner, thus maintaining consistent therapeutic concentrations to manage symptoms and enhance patient compliance. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Consequently, the increasing prevalence of chronic diseases is fueling the transmucosal drug delivery devices market.

    Which Segments Are Contributing To The Growth Of The Transmucosal Drug Delivery Devices Market?

    The transmucosal drug delivery devices market covered in this report is segmented –

    1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films

    2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays

    3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators

    4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels

    5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels

    Which Trends Are Shaping Activity Within The Transmucosal Drug Delivery Devices Market?

    Major companies in transmucosal drug delivery devices are developing innovative smart platforms, including proprietary transdermal patch delivery platforms that enhance drug absorption and improve patient compliance and convenience. Proprietary transdermal patch delivery platforms are specialized technologies owned by companies for administering medications through the skin, ensuring controlled release and enhanced therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, launched STARSILON, a novel proprietary transdermal patch delivery platform, for a longer duration to achieve therapeutic delivery of difficult-to-formulate APIs. It expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.

    Who Are The Primary Competitors In The Global Transmucosal Drug Delivery Devices Market?

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    Which Regions Are Poised For Strategic Growth In The Transmucosal Drug Delivery Devices Market?

    North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Transmucosal Drug Delivery Devices Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2026, By The Business Research Company

    Oral Transmucosal Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report

    Drug Delivery Devices Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Drug Delivery Devices Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

  • Transmucosal Drug Delivery Devices Market Insights: Revenue Expected to Surpass $76.06 Billion by 2029

    Transmucosal Drug Delivery Devices Market Insights: Revenue Expected to Surpass $76.06 Billion by 2029

    Uncover key drivers, emerging technologies, and competitive movements shaping the transmucosal drug delivery devices market from 2025–2034 with trusted insights from The Business Research Company

    What Is The Current Size And Expected Growth Outlook For The Transmucosal Drug Delivery Devices Market?

    The transmucosal drug delivery devices market size has seen significant growth in recent years. This market is set to increase from $50.24 billion in 2024 to $54.63 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.7%. The expansion observed in the past can be attributed to the necessity for swift relief from angina, the efficiency of sublingual delivery for rapid bloodstream absorption, the desire to avoid gastrointestinal degradation, the innovation of buccal tablets, and the demand for non-invasive administration of peptides and proteins.

    The transmucosal drug delivery devices market is anticipated to experience substantial growth over the next few years. It is projected to expand to $76.06 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.6%. This expected growth during the forecast period is attributable to the advancement of smart drug delivery systems, a rising incidence of chronic diseases, an increasing emphasis on personalized medicine, an aging population with elevated medication requirements, and heightened awareness. Significant trends for the forecast period include an expansion in therapeutic applications, the tailoring of drug delivery devices for personalized medicine, evolving regulatory approvals and guidelines, the emergence of new markets, the development of eco-friendly devices, and the creation of innovative formulations.

    Access A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    Which Growth Drivers Are Propelling The Transmucosal Drug Delivery Devices Market?

    The increasing occurrence of chronic illnesses is anticipated to fuel the expansion of the transmucosal drug delivery devices market moving forward. A chronic illness is characterized as a long-term ailment that typically develops slowly and persists over an extended period, frequently necessitating ongoing medical care to manage its symptoms and avert complications. The rise in chronic diseases can be attributed to factors such as lifestyle choices, an aging populace, environmental influences, challenges within healthcare systems, and increasing urbanization. Transmucosal drug delivery devices find application in chronic conditions by enabling precise and effective medication dispersion, which helps sustain therapeutic concentrations for symptom management and enhances patient adherence. For instance, in August 2023, a report from the US-based charitable organization, the Leukemia & Lymphoma Society (LLS), indicated that in the US, roughly every three minutes, an individual receives a diagnosis of leukemia, lymphoma, or myeloma. For 2023, approximately 184,720 people are projected to be diagnosed with these conditions, which constitutes 9.4% of the forecasted 1,958,310 new cancer diagnoses for the year. Consequently, the expanding prevalence of chronic diseases is a key factor driving the transmucosal drug delivery devices market.

    Which Segmentation Factors Are Most Significant In The Transmucosal Drug Delivery Devices Market Analysis?

    The transmucosal drug delivery devicesmarket covered in this report is segmented –

    1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems

    2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation

    Which Notable Trends Are Transforming The Transmucosal Drug Delivery Devices Market Outlook?

    Leading companies in transmucosal drug delivery devices are innovating smart platforms, such as proprietary transdermal patch delivery systems, which are designed to enhance drug absorption and improve patient compliance and convenience. Proprietary transdermal patch delivery platforms represent specialized, company-owned technologies for administering medications through the skin, ensuring controlled release and improved therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, introduced STARSILON, a new proprietary transdermal patch delivery platform, intended for longer duration to achieve the therapeutic delivery of active pharmaceutical ingredients (APIs) that are difficult to formulate. This expands transdermal drug delivery options for challenging APIs, thereby enhancing therapeutic efficacy with sustained delivery rates.

    Who Are The Most Influential Companies In The Transmucosal Drug Delivery Devices Market?

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

    Download The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    Which Region Holds The Largest Share In The Transmucosal Drug Delivery Devices Market Today?

    North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get A Report Customized For You Here:

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2025, By The Business Research Company

    Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Injectable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

    Implantable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Transmucosal Drug Delivery Devices Industry Trends: Where the Market Is Headed by 2029

    Global Transmucosal Drug Delivery Devices Industry Trends: Where the Market Is Headed by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Much Larger Is The Transmucosal Drug Delivery Devices Market Expected To Become By 2029 Compared With Its 2025 Level?

    The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $50.24 billion in 2024 to $54.63 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the need for rapid relief from angina, the effectiveness of sublingual delivery for quick absorption into the bloodstream, desire to bypass gastrointestinal degradation, development of buccal tablets, the need for non-invasive delivery of peptides and proteins.

    The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $76.06 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the development of smart drug delivery systems, increased prevalence of chronic diseases, growing focus on personalized medicine, aging population with higher medication needs, and increased awareness. Major trends in the forecast period include expansion in therapeutic applications, customizing drug delivery devices for personalized medicine, regulatory approvals and guidelines, emerging markets, eco-friendly devices, and innovative formulations.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    What Are The Emerging Market Drivers Creating New Opportunities In The Transmucosal Drug Delivery Devices Industry?

    The growing prevalence of chronic diseases is expected to propel the growth of the transmucosal drug delivery devices market going forward. A chronic disease refers to a long-lasting condition that typically progresses slowly and persists over time, often requiring ongoing medical management to control symptoms and prevent complications. Chronic diseases are rising as a result of, lifestyle factors, aging populations, environmental factors, healthcare system challenges, and urbanization. Transmucosal drug delivery devices are used in chronic diseases to provide controlled and efficient delivery of medications, ensuring sustained therapeutic levels for managing symptoms and improving patient adherence. For instance, in August 2023, according to a report published by the Leukemia & Lymphoma Society (LLS), a US-based charitable organization, in the US, approximately every three minutes, someone is diagnosed with leukemia, lymphoma, or myeloma. In 2023, an estimated 184,720 individuals are expected to receive these diagnoses, representing 9.4% of the projected 1,958,310 new cancer cases for the year. Therefore, growing prevalence of chronic diseases is driving the transmucosal drug delivery devices market.

    What Are The Emerging Segments Gaining Attention In The Transmucosal Drug Delivery Devices Market?

    The transmucosal drug delivery devicesmarket covered in this report is segmented –

    1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems

    2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation

    Which Market Trends Are Creating New Opportunities In The Transmucosal Drug Delivery Devices Industry?

    Major companies operating in transmucosal drug delivery devices are developing innovative smart platform, such as proprietary transdermal patch delivery platforms that enhance drug absorption and improve patient compliance and convenience. Proprietary transdermal patch delivery platforms refer to specialized technologies owned by companies for administering medications through the skin, ensuring controlled release, and enhanced therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, launched STARSILON, a novel proprietary transdermal patch delivery platform, for a longer duration to achieve therapeutic delivery of difficult-to-formulate APIs. It expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.

    Which Industry Leaders Are Driving Innovation Across The Transmucosal Drug Delivery Devices Market?

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    How Does The Transmucosal Drug Delivery Devices Market Perform Across Key Geographic Regions?

    North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Transmucosal Drug Delivery Devices Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2025, By The Business Research Company

    Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Injectable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

    Implantable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Emerging Trends Redefining the Transcatheter Embolization And Occlusion Devices Market Landscape: Innovative Technologies Transforming Transmucosal Drug Delivery Devices

    Emerging Trends Redefining the Transcatheter Embolization And Occlusion Devices Market Landscape: Innovative Technologies Transforming Transmucosal Drug Delivery Devices

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has The Transmucosal Drug Delivery Devices Market Size Shifted, And What Is the Outlook Through 2034?

    In recent years, there has been a robust growth in the market size of transmucosal drug delivery devices. The market is set to expand from $50.24 billion in 2024 to $54.63 billion in 2025, earmarking a compound annual growth rate (CAGR) of 8.7%. Several factors have contributed to this growth during the historical period; these include the demand for immediate relief from angina, efficiency of sublingual delivery for fast absorption into the bloodstreams, the necessity to bypass gastrointestinal degradation, the creation of buccal tablets, and the need for non-invasive methods of delivering peptides and proteins.

    In the upcoming years, the market for transmucosal drug delivery devices is projected to experience robust growth. The market is forecasted to reach a size of $76.06 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.6%. This growth is expected due to several contributing factors such as the emergence of intelligent drug delivery systems, a rise in chronic disease prevalence, an increased emphasis on personalized medicine, an aging population requiring more medication, and heightened awareness. Key trends for this period include the widening therapeutic applications, the customization of drug delivery devices for personalized medicine, regulatory approvals and guidance, emerging markets, environmentally-friendly devices, and novel formulations.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    What Are the Core Market Drivers Propelling Growth in the Transmucosal Drug Delivery Devices Industry?

    The predicted increase in chronic diseases is likely to fuel the growth of the transmucosal drug delivery devices market. Chronic diseases, characterized by slow progression and duration, often require effective medical management to keep symptoms and complications in check. The rise in chronic diseases results from lifestyle factors, aging populations, environmental influences, healthcare system issues, and urbanization. Transmucosal drug delivery devices are utilized for chronic conditions to deliver controlled and effective drug doses, assuring maintained therapeutic levels for symptom control and improving adherence in patients. For example, in August 2023, the Leukemia & Lymphoma Society (LLS), a charity based in the US, reported that roughly every three minutes, a diagnosis is made for leukemia, lymphoma, or myeloma. These diagnoses were expected to total 184,720 in 2023, accounting for 9.4% of the anticipated 1,958,310 new cancer cases that year. Therefore, the escalating rates of chronic diseases propel the market growth of transmucosal drug delivery devices.

    How Is the Transmucosal Drug Delivery Devices Market Segmented?

    The transmucosal drug delivery devicesmarket covered in this report is segmented –

    1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems

    2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Which Regions Are Driving the Next Phase of the Transmucosal Drug Delivery Devices Market Growth?

    North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Key Market Trends and Innovations Are Shaping the Future of the Transmucosal Drug Delivery Devices Industry?

    Leading companies in the field of transmucosal drug delivery devices are pioneering new smart platforms including proprietary transdermal patch delivery systems. These innovative platforms boost drug absorption, increase patient adherence and make administration more convenient. A proprietary transdermal patch delivery platform is a specialized technology, owned by a particular company, designed to administer medication through the skin. It’s made to ensure a controlled release and enhance therapeutic results. For example, in January 2024, a US biotech firm, Starton Therapeutics Inc, introduced STARSILON. This is a unique proprietary transdermal patch delivery platform intended for extended use to deliver difficult-to-formulate APIs. It broadens the scope of transdermal drug delivery for challenging active pharmaceutical ingredients (APIs), improving therapeutic effectiveness through sustained delivery rates.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    How Is the Transmucosal Drug Delivery Devices Market Defined and What Are Its Core Parameters?

    Transmucosal drug delivery devices are medical devices designed to deliver drugs through the mucous membranes, such as those in the mouth, nose, or rectum, for rapid absorption into the bloodstream. These devices are used to administer medications that are poorly absorbed by the gastrointestinal tract or that require quick onset of action, such as pain relief or hormone therapy. Their purpose is to bypass the digestive system, providing a more direct and efficient route for drug delivery.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Transmucosal Drug Delivery Devices Market Projected at $78.21 Billion by 2029 | Strategic Insights and Forecast Data

    Transmucosal Drug Delivery Devices Market Projected at $78.21 Billion by 2029 | Strategic Insights and Forecast Data

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    #How Has The Transmucosal Drug Delivery Devices Market Size Shifted, And What Is the Outlook Through 2034?_x000D_

    The market for transmucosal drug delivery devices has seen significant expansion in the past few years. The market size is predicted to increase from $50.24 billion in 2024 to $55.04 billion in 2025, marking a compound annual growth rate (CAGR) of 9.6%. Factors such as the demand for speedy relief from angina, the efficacy of sublingual administration for quick blood absorption, the preference to avoid gastrointestinal degradation, the emergence of buccal tablets, and the requirement for non-invasive delivery of peptides and proteins have contributed to the growth during the historic period._x000D_

    _x000D_

    #How Much Will the Transmucosal Drug Delivery Devices Market Be Worth in 2029?#_x000D_

    The market for transmucosal drug delivery devices is predicted to witness significant growth in the coming years, expanding to $78.21 billion by 2029 at a compound annual growth rate (CAGR) of 9.2%. The key drivers of this growth during the forecast period include advancements in smart drug delivery systems, the rising incidence of chronic illnesses, an increasing emphasis on personalized treatment, the growing medication demands of an aging population, and heightened awareness. Dominant trends anticipated for the forecast period encompass the broadening of therapeutic applications, the tailoring of drug delivery devices for personalized medicine, regulatory consent and guideline development, the emergence of new markets, the rise of environmentally friendly devices, and inventive formulations._x000D_

    _x000D_

    #Download The Free Sample Report Here:#_x000D_

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp_x000D_

    _x000D_

    #Which is the Largest Company in the Transmucosal Drug Delivery Devices Market?#_x000D_

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd._x000D_

    _x000D_

    #What Are the Main Market Drivers in the Transmucosal Drug Delivery Devices Industry?#_x000D_

    The increasing occurrence of chronic ailments is predicted to stimulate the expansion of the transmucosal drug delivery devices market in the future. Chronic diseases, typically slow-progressive and persistent conditions requiring constant medical intervention to manage symptoms and prevent complications, are on rise due to lifestyle changes, aging populations, environmental influences, challenges in healthcare systems, and urbanisation. Transmucosal drug delivery devices play a crucial role in chronic disease treatment by ensuring controlled and effective medication delivery, which in turn maintains therapeutic levels and boosts patient compliance. For example, a report from the Leukemia & Lymphoma Society (LLS), a charity organisation in the US, stated in August 2023 that every three minutes, someone in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2023, around 184,720 individuals are anticipated to be diagnosed with these diseases, accounting for 9.4% of the projected 1,958,310 new cancer cases for that year. Consequently, the escalating prevalence of chronic diseases is fueling the growth of the transmucosal drug delivery devices market._x000D_

    _x000D_

    #Request For A Customized Report:#_x000D_

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp_x000D_

    _x000D_

    #How Is the Transmucosal Drug Delivery Devices Market Segments Structured?#_x000D_

    The transmucosal drug delivery devices market covered in this report is segmented –_x000D_

    _x000D_

    1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery_x000D_

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types_x000D_

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications_x000D_

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems_x000D_

    2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation_x000D_

    _x000D_

    #What Strategic Trends Are Transforming the Transmucosal Drug Delivery Devices Market?#_x000D_

    Leading firms in the transmucosal drug delivery device sector are pioneering innovative smart platforms, such as unique transdermal patch delivery systems, to augment drug absorption while improving patient adherence and ease of use. Transdermal patch delivery platforms essentially denote specialized technologies that are company-owned, used to dispense medications via the skin for controlled release and better therapeutic results. For example, in January 2024, Starton Therapeutics Inc, a biotech firm from the US, introduced STARSILON, its new exclusive transdermal patch delivery platform. It was launched to provide therapeutic delivery of complex-to-formulate APIs over prolonged periods. This enhances transdermal drug delivery choices for challenging active pharmaceutical ingredients (APIs) and improves therapeutic effectiveness through sustained delivery rates._x000D_

    _x000D_

    #Access The Full Report Here:#_x000D_

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report_x000D_

    _x000D_

    #Which Global Regions Offer the Highest Growth in the Transmucosal Drug Delivery Devices Market?#_x000D_

    North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

    _x000D_

    #Purchase The Full Report Today:#_x000D_

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812_x000D_

    _x000D_

    #This Report Delivers Insight On: #_x000D_

    1. How big is the transmucosal drug delivery devices market, and how is it changing globally?_x000D_

    2. Who are the major companies in the transmucosal drug delivery devices market, and how are they performing?_x000D_

    3. What are the key opportunities and risks in the transmucosal drug delivery devices market right now?_x000D_

    4. Which products or customer segments are growing the most in the transmucosal drug delivery devices market?_x000D_

    5. What factors are helping or slowing down the growth of the transmucosal drug delivery devices market?_x000D_

    _x000D_

    #About The Business Research Company:#_x000D_

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

    _x000D_

    #Get in touch with us:#_x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas +1 310-496-7795_x000D_

    Asia +44 2071930708_x000D_

    Europe +44 7882 955267_x000D_

    Email us at info@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Transmucosal Drug Delivery Devices Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

    Transmucosal Drug Delivery Devices Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

    Discover trends, market shifts, and competitive outlooks for the transmucosal drug delivery devices industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    #How Has the Transmucosal Drug Delivery Devices Market Growth Performance Trended Historically, And What Lies Ahead?3

    There has been a significant expansion in the market size of transmucosal drug delivery devices in recent years. This market is set to balloon from $50.24 billion in 2024 to $55.04 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.6%. The previous growth can be traced back to several factors; the urgency for swift angina relief, the utilization of sublingual delivery for swift absorption into the bloodstream, the aim to evade gastrointestinal degradation, the creation of buccal tablets, and the demand for non-invasive peptide and protein delivery.

    The market for transmucosal drug delivery devices is anticipated to witness robust expansion in the following years, surging to a value of $78.21 billion in 2029 with a 9.2% compound annual growth rate (CAGR). The predicted growth during this period can be linked to the progress in sophisticated drug delivery systems, high occurrence of persistent diseases, a trending interest in tailored medicine, an aging demographic requiring more medication, and enhanced consciousness. Key trends noted for the forecast period are the widening in healing uses, modification of drug delivery devices to suit personalized medicine, endorsements and directives from regulatory bodies, emerging markets, environment-friendly devices, and innovative concoctions.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    Which Primay Drivers Are Accelerating Growth in the Transmucosal Drug Delivery Devices Market?

    The upward trend in chronic illnesses is predicted to fuel the transmucosal drug delivery devices market’s expansion. Chronic illnesses, which normally develop gradually and persist, necessitate continuous medical intervention to curb symptoms and stave off complications. Rising lifestyle-related issues, an aging populace, environmental influences, healthcare system issues, and urbanization contribute to an increase in chronic illnesses. Transmucosal drug delivery devices are utilized for these enduring diseases, offering controlled and effective medication delivery, maintaining consistent therapeutic levels, and enhancing patient compliance. For instance, a report released by the Leukemia & Lymphoma Society (LLS), a charity organization in the US, stated that in August 2023, someone gets diagnosed with Leukemia, Lymphoma, or Myeloma every three minutes in the US. In 2023, about 184,720 individuals are anticipated to receive these diagnoses, accounting for 9.4% of the projected 1,958,310 new cancer cases for that year. Consequently, the escalating prevalence of chronic diseases is stimulating the growth of the transmucosal drug delivery devices market.

    What Segment Types Define the Transmucosal Drug Delivery Devices Market Structure?

    The transmucosal drug delivery devices market covered in this report is segmented –

    1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems

    2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Which Regions Are Key Players in the Growth of the Transmucosal Drug Delivery Devices Market?

    North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Emerging Trends that Are Influencing the Transmucosal Drug Delivery Devices Industry Evolution?

    Leading firms in the transmucosal drug delivery device sector are focusing on the creation of novel smart platforms, such as unique transdermal patch delivery systems, to increase drug absorption and augment patient convenience and compliance. These unique transdermal patch delivery platforms represent specific technologies that companies own to facilitate the administration of medicines via the skin, guarantee a controlled release, and improve therapeutic results. For instance, Starton Therapeutics Inc., a biotech company from the US, introduced STARSILON in January 2024 – a distinctive proprietary transdermal patch delivery platform, designed for long-term therapeutic administration of difficult-to-formulate active pharmaceutical ingredients (APIs). This development widens the scope of transdermal drug delivery possibilities for complex APIs, augmenting therapeutic potency by offering sustained delivery rates.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    What Is the Definition of the Transmucosal Drug Delivery Devices Market?

    Transmucosal drug delivery devices are medical devices designed to deliver drugs through the mucous membranes, such as those in the mouth, nose, or rectum, for rapid absorption into the bloodstream. These devices are used to administer medications that are poorly absorbed by the gastrointestinal tract or that require quick onset of action, such as pain relief or hormone therapy. Their purpose is to bypass the digestive system, providing a more direct and efficient route for drug delivery.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Top Growth Trends in the Transmucosal Drug Delivery Devices Market: Insights into Market Size and Opportunities for 2025-2034

    Top Growth Trends in the Transmucosal Drug Delivery Devices Market: Insights into Market Size and Opportunities for 2025-2034

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    What Are the Primary Drivers Supporting the Market Growth of theTransmucosal Drug Delivery Devices Market?

    The growing prevalence of chronic diseases is expected to propel the growth of the transmucosal drug delivery devices market. Chronic diseases require ongoing treatment to manage symptoms and prevent complications. Transmucosal drug delivery devices provide controlled medication delivery, ensuring sustained therapeutic effects. For instance, in August 2023, the Leukemia & Lymphoma Society reported an estimated 184,720 new diagnoses of leukemia, lymphoma, or myeloma in 2023. Therefore, the growing prevalence of chronic diseases is driving the transmucosal drug delivery devices market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

    #How Does the ProjectedTransmucosal Drug Delivery Devices Market Growth Compare Over the Forecast Period?

    The transmucosal drug delivery devices market size will grow from $50.24 billion in 2024 to $55.04 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth is linked to the need for rapid relief from angina, the effectiveness of sublingual delivery, the development of buccal tablets, and the demand for non-invasive peptide and protein delivery.

    The transmucosal drug delivery devices market is expected to grow strongly, reaching $78.21 billion by 2029 with a CAGR of 9.2%. This growth is driven by the development of smart drug delivery systems, increasing prevalence of chronic diseases, growing focus on personalized medicine, an aging population with increased medication needs, and higher awareness. Trends include expanding therapeutic applications, customization for personalized medicine, regulatory advancements, eco-friendly devices, and innovative drug formulations.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812

    What Are the Latest Innovations Influencing theTransmucosal Drug Delivery Devices Market?

    Companies in the transmucosal drug delivery devices market are developing innovative smart platforms, like proprietary transdermal patch delivery systems, to improve drug absorption, patient compliance, and convenience. In January 2024, Starton Therapeutics Inc., a US-based biotechnology company, launched STARSILON, a proprietary transdermal patch delivery platform designed for sustained delivery of difficult-to-formulate APIs. This platform expands transdermal delivery options for challenging active pharmaceutical ingredients, improving therapeutic efficacy.

    Who Are the Major Industry Players Accelerating Growth in theTransmucosal Drug Delivery Devices Market?

    Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

    Which Primary Segments of the Transmucosal Drug Delivery Devices Market Are Driving Growth and Industry Transformations?

    The transmucosal drug delivery devices market covered in this report is segmented –

    1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery

    2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types

    3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications

    4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

    Subsegments:

    1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems

    2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

    Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theTransmucosal Drug Delivery Devices Market?# Market?

    North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Transmucosal Drug Delivery Devices Market 2025, By The Business Research Company:

    Implantable Drug Delivery Devices Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Injectable Drug Delivery Devices Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

    Drug Delivery Devices Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: